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Abstract
Background: G protein coupled receptors (GPCRs) represent the largest family of membrane proteins in the
human genome and the richest source of targets for the pharmaceutical industry. A major limitation to
characterizing GPCRs has been the difficulty in developing high-level heterologous expression systems that are cost
effective. Reasons for these difficulties include inefficient transport and insertion in the plasma membrane and
cytotoxicity. Additionally, GPCR purification requires detergents, which have a negative effect on receptor yields
and stability.
Results: Here we report a detergent-free cell-free protein expression-based method to obtain pharmacologically
active GPCRs in about 2 hours. Our strategy relies on the co-translational insertion of modified GPCRs into
nanometer-sized planar membranes. As a model we employed an engineered b2-adrenergic receptor in which the
third intracellular loop has been replaced with T4 lysozyme (b2AR -T4L). We demonstrated that nanolipoprotein
particles (NLPs) are necessary for expression of active b2AR -T4L in cell-free systems. The binding specificity of the
NLP- b2AR-T4L complex has been determined by competitive assays. Our results demonstrate that b2AR-T4L
synthesized in vitro depends on similar oxidative conditions as those required by an in vivo-expressed receptor.
Conclusions: Although the activation of b2AR-T4L requires the insertion of the T4 lysozyme sequence and the
yield of that active protein limited, our results conceptually prove that cell-free protein expression could be used as
a fast approach to express these valuable and notoriously difficult-to-express proteins.
Background
With over 1000 members, G-protein-coupled receptors
represent the largest family of integral membrane pro-
teins, whose corresponding genes span > 1% of the
human genome [1]. Despite their remarkable topological
similarity (they all have a seven-transmembrane -a-heli-
cal topology), they respond to a plethora of extracellular
stimuli, mediating cellular responses to hormones, neu-
rotransmitters and senses such as smell, taste, and sight.
Their relevance in signal transduction and their extraor-
dinary diversity have turned them into the most pursued
drug targets (> 60% of the industry), which generate $50
billion in pharmaceutical sales per year [2].
Major limitations to studying GPCRs include the diffi-
culties in using high-level heterologous expression
platforms (being baculoviral-mediated and transient
mammalian expression the most commonly used) and
the unpredictability of the expression outcome. It is
apparent that the folding mechanism and stability of
these molecules in their native systems are quite com-
plex. This notion imposes a key obstacle, as the natural
abundance of these proteins is too low to purify suffi-
cient material for functional and structural studies.
Another difficulty is that GPCRs are naturally
embedded in a complex and dynamic lipid bilayer,
which restricts the use of many standard biophysical
techniques used for studying soluble proteins. The use
of detergents is often questioned, as it is unclear how
well micelle structures mimic the natural membrane
protein environment. On the other hand, reconstitution
of GPCRs into artificial bilayers is not a trivial process,
and results in structures that are too heterodisperse to
be used in structural studies. * Correspondence: toni.kudlicki@liftech.com
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inherent conformational plasticity. With the exception
of rhodopsin, which is locked into an inactive state by
its covalently bound inverse agonist 11-cys-retinal,
GPCRs adopt different states of activity, which precludes
determining their tridimensional structure [3]. Recent
breakthroughs have been the resolution of ligand bound
inactive-state structures of GPCRs [4-9], where a variety
of protein modifications and engineering approaches
were applied to stabilize the proteins.
Cell-free protein expression is increasingly being con-
sidered as viable alternative for overcoming the above
obstacles (for a recent review see [10]). However, all
current cell-free approaches used to express functional
GPCRs require protein solubilization in detergent
micelles or reconstitution into lipid membranes [11-14].
In order to circumvent these obstacles, we have recently
proposed a novel cell-free protein expression strategy
based on the use of ‘nanodiscs’ or ‘nanolipoprotein par-
ticles’ (NLPs) [15,16].
NLPs are self-assembled discoidal particles composed
of a planar phospholipid membrane bilayer surrounded
by an apolipoprotein ring (scaffold protein) [17]. The
approach makes use of NLPs, which are either added to
or in situ assembled in the cell-free reaction, providing
support for the nascent membrane protein and thereby
circumventing subsequent protein extraction and recon-
stitution steps. The main limitation is that wild-type
GPCRs expressed under these conditions lack ligand
binding activity (unpublished results).
Here we report the cell-free synthesis of functional
human adrenergic b2 receptor (b2AR) that has been sta-
bilized through the insertion of the T4 bacteriophage
lysozyme (b2AR-T4L) [5]. We also show that ligand
binding activity is attainable without the need of deter-
gent solubilization or membrane reconstitution.
Results
b2AR-T4L complexes with NLPs and binds a specific
antagonist - relevance of the lysozyme insertion
In an effort to produce functional GPCRs in vitro with-
out relying on detergent solubilization or membrane
reconstitution, nine members of this receptor family
were expressed in the presence of NLPs [15]. Unfortu-
nately, none of them, albeit associated with NLPs, exhib-
ited ligand binding activity (results not shown). After
numerous unsuccessful attempts that involved the
reworking of the expression conditions, the addition of
folding catalysts, and the use of a variety of N- and C-
terminal fusion partners, we focused our attention on a
recently reported stabilized variant of b2AR [5,6]. The
molecule harbors a T4 lysozyme insertion within the
third intracellular loop, which does not impair critical
biochemical consequences on the receptor other than
slightly elevated agonist binding affinities [5,6]. When
this protein was expressed in our cell-free protein
expression system in the presence of NLPs, specific and
displaceable binding to the antagonist [
3H]-dihydroal-
prenolol ([
3H]DHA) was observed (Figure 1A and 1B).
In contrast, b2AR failed to exhibit binding even though
identical reaction conditions were applied (Figure 1A
and 1B). Additional experiments showed that other non-
specific ligands failed to bind the NLP- b2AR-T4L com-
plex (not shown). The receptor variants (b2AR-T4L and
b2AR) expressed at similar levels (Figure 1C), and com-
plexed with the NLPs in a similar fashion, generating a
supramolecular complex of an apparent weight of about
250 kDa (Figure 1D). However, only b2AR-T4L was able
to bind [
3H]DHA (Figure 1A). Previous reports indi-
cated that cholesterol was relevant in the stability and
function of b2AR [18,19]. However, in our conditions,
the addition of cholesterol to the reaction did not result
in significant changes in the activity of in vitro expressed
b2AR or b2AR-T4L (not shown). Taken together, these
results suggest that the insertion of the T4 lysozyme
moiety (major difference between the two receptor var-
iants) may play a crucial role assisting the molecule to
attain a functional and/or more stable conformation in
preformed NLPs.
Pharmacological characterization of cell-free expressed
b2AR-T4L
In order to assess whether b2AR-T4L was properly
folded, we determined its ligand binding constants. Our
approach combines cell-free protein expression and
ligand binding in a single reaction. The radioligand is
added at time zero, and binding takes place as proteins
are translated and complexed with the NLPs. Protein
concentration and folding is driven by the amount of
programming DNA and reaction conditions. Therefore,
higher variability than in conventional ligand binding
assays is expected. Saturable affinity binding curves were
obtained using [
3H]DHA as the radioligand, and propra-
nolol as the unlabelled competitor. Results showed that
the dissociation constant (Kd) of the cell-free product
(Figure 2A) was close to what is observed with b2AR-
T4L expressed and purified from insect cells (Figure
2B), However, the estimated maximal number of recep-
tor binding sites (Bmax) for the cell-free made protein
was significantly lower than that one produced in insect
cells (compare Figure 2A with 2B). These findings, as
will be discussed below, suggest that only a small frac-
tion of the total protein produced attained its proper
active conformation.
One way to estimate the amount of active receptor
produced stems from the calculated Bmax parameter (9
fmol DHA/μg receptor). Assuming one binding site per
molecule (MW = 56941 Da), and knowing that the
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35S]Met trace label-
ing) was 100 μg/ml, 51 ng of GPCR/ml of reaction was
obtained. A second approach to estimate that value is
through the equation “Bmax cell-free expressed recep-
tor/Bmax insect cell-expressed receptor × yield cell-free
expressed receptor”, assuming the insect-cells expressed
protein is fully functional. Applying the latter formula
the total amount of active receptor per ml of reaction
should be 65 ng/ml, very close to the number above.
Differences inherent to the expression platform used
(insect cells vs. prokaryote cell-free) such as post-trans-
lational modifications, membrane composition, and sam-
ple processing may also account for this discrepancy.
To further characterize the cell-free expressed recep-
tor, affinity competition experiments were carried out.
The natural antagonist epinephrine and the high-affinity
synthetic agonist formoterol were used (Figure 3). The
relative affinities for these ligands was similar as that
one observed using membranes isolated from insect
cells expressing b2AR-T4L [5].
Taken together, the results above suggest the protein
synthesized in vitro exhibit similar pharmacological
properties as those described earlier [5]. These findings
validate the cell-free proteine x p r e s s i o na p p r o a c ha sa
viable vehicle to obtain functional b2AR-T4L, albeit
with limited folding capacity.
Oxidative protein folding is required for ligand binding
Early reports showed that two extracellular disulfide bonds
in the wild type b2AR are required for ligand binding
[20,21]. More recently, it was shown that the ligand acces-
sibility in b2AR-T4L is enabled by these pairs of closely
spaced disulfide bridges [6]. To verify that the activity of
the in vitro expressed b2AR-T4L still relies on disulfide
bond formation, we expressed this protein using cell-free
expression systems with different reducing strengths. The
results showed that increasing reducing potential is detri-
mental to the ligand binding capacity of b2AR-T4L (Figure
4A). In addition derivatives of this protein where two of
the essential cysteines were replaced by serine residues
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Figure 1 Antagonist binding of the b2AR-T4L-NLP complex. A) Cell-free protein expression was performed in the presence of 40 nM [
3H]
DHA. The unbound isotope was removed by affinity purification and binding was determined as described in methods. B) Similar reactions as in
A) were performed in the presence of NLPs with or without excess of unlabeled propranolol. Two unrelated GPCR proteins 5HT1a and CHRM1
were used as negative controls. C) Similar reactions as in A) were performed in the presence of 1.5 mM [
35S]Met. Proteins were separated by
SDS-PAGE and visualized by autoradiography. D) Products from the reaction described in C) were separated by native electrophoresis and
visualized by autoradiography. Bands with an apparent MW of 720 Kd are non-specific. Experiments in (A)-(D) were performed using the
MembraneMax Protein Expression Kit (Life Technologies, Carlsbad, CA) employing DTT-free buffers with the indicated modifications (see
methods).
Yang et al. BMC Biotechnology 2011, 11:57
http://www.biomedcentral.com/1472-6750/11/57
Page 3 of 8produced receptors with significantly lower specific bind-
ing activity (Figure 4B).
In summary, our results demonstrate that b2AR-T4L
synthesized in vitro, depends on similar oxidative condi-
tions as those required by an in vivo expressed protein.
Discussion
The primary objective of our work was to find a practi-
cal solution to the limitations of GPCR expression
imposed by heterologous systems. Although relatively
large amounts of membrane proteins can be potentially
produced in cellular systems, usually a small proportion
becomes associated to the membrane [22]. Particularly,
GPCRs are confronted to a complex array of trafficking
signals, post-translational modifications, and transport
systems before reaching the final destination, the plasma
membrane. In addition, differences in the lipid bilayer
composition and maximal tolerated membrane protein
loads can additionally affect the correct insertion, fold-
ing, and yield of recombinant GPCRs.
In order to overcome these difficulties, we developed a
cell-free expression system supplemented with planar
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Figure 2 Functional characterization of b2AR-T4L. (A) The protein was expressed in vitro and ligand binding was assessed on crude material
as described in the text. Protein yield was estimated by trace-labeling with [
35S]Met. As a control, purified receptor expressed in insect cells [5]
was used. (B). Binding assays for (A) and (B) were performed as described in methods [5]. Propranolol was used as the unlabeled competitor.
Experiments in (A) were performed using The MembraneMax Protein Expression Kit (Life Technologies, Carlsbad, CA) using DTT-free buffers with
the indicated modifications (see methods). Kd and Bmax values were calculated using GraphPad PRISM software (GraphPad Software, San Diego,
CA). Abbreviations: NSB, non-specific binding;
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Figure 3 Affinity competition curves for adrenergic ligands. Binding experiments were performed on crude material from cell-free reactions
as described in methods using [
3H]DHA and the indicated unlabelled competitors.
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Figure 4 Disulfide bond requirements for b2AR-T4L. (A). Ligand binding assays for b2AR-T4L expressed in vitro was performed as described
in Fig. 1 using the MembraneMax Protein Expression system (Life Technologies, Carlsbad, CA) following the manufacturer’s directions, which
results in 1.0 mM DTT in the reaction; or using DTT-free buffers, which results in 0.2 mM DTT in the reaction; or using the RTS 100 E. coli
Disulfide Kit (Roche Applied Science, Indianapolis, IN), which is designed for synthesis of disulfide-bonded proteins (detailed composition
unknown). All reactions were performed in the presence of NLPs and either 0.5 nM
[3H]DHA (for ligand binding determination) or [
35S]Met (for
protein quantity assessment). [
35S]Met trace-labeled products were separated by SDS electrophoresis, and visualized by autoradiography). (B)
Reactions using b2AR-T4L and two cysteine mutant derivatives were performed using the MembraneMax Protein Expression system
supplemented with DTT-free buffers and processed as described in (A).
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expressing soluble membrane protein products, it fails
to produce functional GPCRs. We favor the absence of
a functional translocon machinery embedded in the
membrane particles as one of the major reasons for this
negative outcome.
We reasoned that a way to overcome this deficiency
would be to employ GPCR derivatives that insert into
the membrane in a translocase-independent fashion (for
a recent review on membrane protein insertion see
[23]). Since there is no in silico approach to establish a
priori the type membrane insertion mechanism of a
given protein, our strategy was to try active variants
reported in the literature. Our attempt was to employ
one of the stable b2AR derivatives recently described,
where the third intracellular loop was replaced by T4
lysozyme [6].
The strategy proved to work. The enzyme complexed
with the NLPs and exhibited similar affinity properties
as those ones reported in vivo [5]. Perhaps the clearest
advantage of this method is its short processing time: it
only takes about 2 hours to go from gene to ligand
binding assay.
Although the cell-free made enzyme showed a similar
dissociation constant as that one made in-vivo, the max-
imal number of ligand sites appeared to be significantly
lower. Namely, only a fraction of the receptors seems to
be active. These findings suggest that additional compo-
nents such as folding catalysts, specific lipid constitu-
ents, post-translational modifications, or a membrane
protein insertion machinery, absent in our reaction con-
ditions, may be required by b2AR-T4L to attain a high
specific activity. Conversely, elimination of some pro-
teases present in the cell-free extract may contribute to
provide a better context for more stable GPCRs. While
this observation does not affect the benefit of this
approach as a rapid screening method for analyzing
GPCR activity, further experimentation is needed to
establish the nature of the deficiency. For example, the
generation of cholesterol-containing NLPs, or the use of
NLPs bearing the SEC translocon would likely shed
light on this subject (for reconstitution of the SecYEG
complex into NLPs see [24]).
The replacement of the third intracellular loop by T4
lysozyme as a strategy to stabilize GPCR molecules has
been proven successful for other GPCR molecules [9].
In addition, other GPCR stabilization approaches have
demonstrated success (see for example [8]). Finally, the
incorporation of unnatural amino acids into crucial
regions of these elusive molecules holds the promise of
overcoming some of these difficulties [25].The assay of
these other variants in our cell-free approach will help
determine what aspects of the GPCR biochemistry are
critical for reaching its proper conformation.
Conclusion
Our results conceptually prove that cell-free protein
expression could be used as a fast approach to express
these valuable and notoriously difficult-to-express pro-
teins. To our knowledge, this was the first time that a
functional GPCR was obtained in a cell-free context,
with no further re-folding or reconstitution require-
ments. The modified cell-free system combined with
NLP offers the unique opportunity to produce sufficient
expression levels of soluble and functional folded GPCR
for pharmacological assays that are difficult to obtain
with other expression systems. Finally, the use of NLPs
with different chemistries should allow fine-tuning of
the conditions optimal for expression and solubilization
of specific MPs in near-native context.
Methods
Plasmids and clones
T h ew i l dt y p ev e r s i o no ft h eh u m a na d r e n e r g i cb2
receptor (b2AR, GenBank acc# NM_000024), human
serotonin receptor 1a (5HT1a, GenBank acc#
NM_000524), human muscarinic 1 receptor (CHRM1,
GenBank acc# NM_000738), were retrieved from the
Ultimate ORF collection (Life Technologies, Carlsbad,
CA), PCR-amplified, and cloned into the plasmid
pEXP5-NT/TOPO (Life Technologies, Carlsbad, CA).
Details of the construct that expresses b2AR-T4L were
published elsewhere [5]. Site directed mutagenesis of the
cysteine residues was performed utilizing the GENEART
site directed mutagenesis kit (Life Technologies, Carls-
bad, CA) employing the following oligonucleotide pairs:
5’-CATCAGGAAGCGATCAACTCCTATGCGGAA-
GAAAC-3’ and 5’-GTTTCTTCCGCATAGGAGTTGA
TCGCTTCCTGATG–3’ (for cysteine 184), and 5’-GG
AAGAAACTTCCTGCGACTTTTTCACCAACCAG
GCG-3’ and 5-CGCCTGGTTGGTGAAAAAGTCGC
AGGAAGTTTCTTCC-3’ (for cysteine 190).
Cell-Free Protein Expression Reactions
Cell-free protein expression was conducted using the
MembraneMax™ Protein Expression Kit (Life Technolo-
gies, Carlsbad, CA) either following the manufacturer’s
direction or replacing the buffers with similar ones devoid
of DTT. Where indicated the RTS 100 E. coli Disulfide Kit
(Roche Applied Science, Indianapolis, IN) was used in a
batch configuration supplementing the reactions with
NLPs as indicated previously [15]. Where indicated, reac-
tions were supplemented with [
35S]Met (135 mCi/mmol
final) (Perkin Elmer, Waltham, MA) or varying amounts
of [
3H]DHA (Perkin Elmer, Walthman, MA) as indicated.
Protein yield and ligand binding determination assays
Yield in cell-free protein expression reactions was deter-
mined by [
35S]Met trace labeling. Reaction products
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Page 6 of 8were separated by SDS-PAGE or by native electrophor-
esis using NativePAGE™ Novex
® 4-16% Bis-Tris Gels
(Life Technologies, Carlsbad, CA) and visualized by
autoradiography.
Binding assays were performed in the presence of [
3H]
DHA added directly to the cell free protein expression
reactions. Non-specific binding was assessed by per-
forming identical reactions in the presence of 1 μM pro-
pranolol (Sigma-Aldrich, Saint Louis, MO) as indicated.
Unbound isotopes, [
35S]Met and[
3H]DHA, were
removed by purifying the protein products through Ni
+2
affinity beads (Life Technologies, Carlsbad, CA) via a
histidine tag fused to the receptor molecule. Briefly, the
binding assay was performed on a 96-well GF/C filter
plate (Perkin Elmer, Walthma n ,M A ) ,p r e - t r e a t e dw i t h
0.3% polyethylenimine (PEI), and washed four times
with 500 μl of ice cold binding buffer (50 mM Tris-HCl,
pH7.4, 150 mM NaCl, 5 mM imidazole). Then 100 μlo f
nickel resin beads were added and washed 5 times with
150 μl of binding buffer. Beads were then suspended in
55 μl of binding buffer and mixed with 45 μl of cell-free
reaction samples for 20 min at RT. The binding reaction
was stopped by washing 5 times with 150 μlo fb i n d i n g
buffer. After air-drying, the filters were introduced into
scintillation vials, mixed with 3 ml scintillation liquid
and measured for bound [
3H]DHA with a Beckman
LS5000 scintillation counter. The binding assay for
insect protein samples was conducted as described [5].
Competition binding reactions were carried out in the
presence of 0.5 nM [
3H]DHA plus increasing concentra-
tions of unlabelled formoterol (MP Biomedicals, Solon,
OH), or epinephrine (USP, Rockville, MD) and pro-
cessed as described above. Raw data was processed and
analyzed using software package GraphPad Prism
(GraphPad Software, San Diego, CA).
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